Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National Implications for Rhythm Management and Stroke Prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Jama. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Crijns HJ, Tjeerdsma G, de Kam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J. 2000;21:1238–1245.
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004;5(Suppl 1):S5–S19.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26:1303–1308.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–2925.
   PubMed Web of Science ®Google Scholar
• Falk RH. Atrial fibrillation. N Engl J Med. 2001;344(14):1067–1078.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Tuinenburg AE, Crijns HJGM, et al. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997;77:309–313.
   PubMed Web of Science ®Google Scholar
• Solti F, Vecsey T, Ke´Kesi V, et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882–886.
   PubMed Web of Science ®Google Scholar
• Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608–2614.
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: patophysiology and therapy. Circ Res. 2013;113:739–753.
   PubMed Web of Science ®Google Scholar
• Chen PS, Chen LS, Fishbein LC, et al. Role of the autonomic nervous system in atrial fibrillation pathophysiology and therapy. Circ Res. 2014;114:1500–1515.
   PubMed Web of Science ®Google Scholar
• Li D, Melnyk P, Feng J, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101(22):2631–2638.
   Web of Science ®Google Scholar
• Nattel S. Ionic determinants of atrial fibrillation and Ca₂₊ channel abnormalities. Circ Res. 1999;85(5):473–476.
   Google Scholar
• Maisel WH, Stevenson LV. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6A):2D–8D.
   PubMed Web of Science ®Google Scholar
• Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563–570.
   PubMed Web of Science ®Google Scholar
• Saksena S, Slee A, Waldo AL, et al., Cardiovascular outcomes in the affirm trial (atrial fibrillation follow-up investigation of rhythm management). Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011;58:1975–1985.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833. PubMed: 12466506
   PubMed Web of Science ®Google Scholar
• Workman AJ, Kane KA, Russell JA, et al. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodeling. Cardiovasc Res. 2003;58:518–525.
   PubMed Web of Science ®Google Scholar
• Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457–462.
   PubMed Web of Science ®Google Scholar
• Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail. 2013;1:21–28.
   PubMed Web of Science ®Google Scholar
• Deitchman D, Perhach JLJR, Snyder RW. Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol. 1980;61:263–277.
   PubMed Web of Science ®Google Scholar
• Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15:324–333.
   PubMed Web of Science ®Google Scholar
• Kreighbaum WE, Matier WL, Dennis RD, et al. Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity. J Med Chem. 1980 Mar;23(3):285–289.
   PubMed Web of Science ®Google Scholar
• Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 8;101(5):558–569.
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Wynn JR, Sundberg L, et al. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990 Jun;15(6):959–967.
   PubMed Web of Science ®Google Scholar
• Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999 Apr;289(1):48–53.
   PubMed Web of Science ®Google Scholar
• Bristow MR, O’Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol investigators. Circulation. 1994 Apr;89(4):1632–1642.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14;110(11):1437–1442.
   PubMed Web of Science ®Google Scholar
• Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288–11293.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. Plos One. 2012;7(10):e44324. DOI:10.1371/journal.pone.0044324
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990 Aug;82(2):473–483.
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar;88(3):223–229.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Roden RL, Lowes BD. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998;21(12 suppl 1):I3–I13.
   PubMed Web of Science ®Google Scholar
• Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 4;80(11):26 L–40L.
   Web of Science ®Google Scholar
• Maack C, Cremers B, Flesh M, et al. Differet intrinsc activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol. 2000;130:1131–1139.
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Mcghie AL, Bedotto JW, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol. 1991 Jan 1;67(1):67–73.
   PubMed Web of Science ®Google Scholar
• Pollock SG, Lystash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990;66:603–607.
   PubMed Web of Science ®Google Scholar
• Woodley SE, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ìschemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426–2441.
   PubMed Web of Science ®Google Scholar
• Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol. 1995 Jun 15;75:1220–1223.
   PubMedGoogle Scholar
• BEST. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667.
   PubMed Web of Science ®Google Scholar
• Aleong RG, Sauer WH, Davis G, et al. Prevention of atrial fibrillation by Bucindolol is dependent on the Beta1 389 Arg/Gly adrenergic receptor polymorphism. J Am Coll Cardiol. 2013;1:338–344.
   Google Scholar
• Tate CW 3rd, Robertson AD, Zolty R, et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail. 2007;13:732–737.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gottlieb S, Bourque JM, et al. BEST Investigators. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. Am J Cardiol. 2005 Mar 1;95(5):558–564.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Murphy GA, Krause –Steinrauf H, et al. Adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21–28.
   PubMed Web of Science ®Google Scholar
• Aleong RG, Sauer WH, Robertson AD, et al. Adrenergic receptor polymorphism and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013;6:137–143.
   PubMed Web of Science ®Google Scholar
• Tisdale JE, BorzaK S, Sabbah HN, et al. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure. J Card Fail. 2006;12:747–751.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Holmes J, Kruni H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235–2243.
   PubMed Web of Science ®Google Scholar
• Na S, Kwok N, Dj H, et al. Bucindolol: a pharmacogenomic perspective on its use in chronic Heart failure. Clin Med Insights Cardiol. 2001;5:55–66.
   Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;4:CD002992.
   Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125(6):2309–2321.
   PubMed Web of Science ®Google Scholar
• Albouaini K, Andron M, Alahmar A, et al. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2(4):535–540.
   PubMedGoogle Scholar
• Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol. 2003 Dec 17;42(12):2128–2134.
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol. 2003 Oct 1;42(7):1238–1245.
   PubMed Web of Science ®Google Scholar
• Balamuthusamy S, Molnar J, Adigopula S, et al. Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. Am J Ther. 2009;16(2):133–142.
   PubMed Web of Science ®Google Scholar
• Reinhart K, White CM Bucindolol: a beta-blocker for the treatment of heart failure. 2009 [updated 2009; cited 2011 Febraury 23]; http://chromatographyonline.findanalytichem.com/lcgc/article/articleDetail
   Google Scholar
• Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 3;42(5):914–922.
   PubMed Web of Science ®Google Scholar
• Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? a meta-analysis of large-scale clinical trials. Am Heart J. 2003;146(5):848–853.
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001 May 5;357(9266):1385–1390.
   PubMed Web of Science ®Google Scholar
• Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc. 2009;84(8):718–729.
   PubMed Web of Science ®Google Scholar
• Bouzamondo A, Hulot JS, Sanchez P, et al. Beta-blocker benefit according to severity of heart failure. Eur J Heart Fail. 2003;5(3):281–289.
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Grayburn PA, Mayer SA, et al. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation. 2003 Nov 11;108(19):2336–2341.
   PubMed Web of Science ®Google Scholar
• MeritHF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353:2001–2007.
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999 Jan 2;353:9–13.
   PubMed Web of Science ®Google Scholar
• A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees. Circulation. 1994;90(4):1765–1773.
   PubMedGoogle Scholar
• Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York heart association class IV chronic congestive heart failure. Am J Cardiol. 2000 Oct 15;86(8):886–889.
   PubMed Web of Science ®Google Scholar
• Coats AJ. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs and Aging. 2006;23(2):93–99.
   PubMed Web of Science ®Google Scholar
• Holland D, Dj K, Sh A, et al. Effects of treatment on exercise tolerance, cardiac function and mortality in heart failure with preserved ejection fraction; a meta-analysis. J Am Coll Cardiol. 2011;57:1676–1686.
   PubMed Web of Science ®Google Scholar
• Genetically targeted therapv for the prevention of symptomatic atrial fibrillation in patients with heart failure (GENETIC-AF). Available from: www.clinicaltrials.gov/ct2/show/NGTO 1970501
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology Foundation American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.
   PubMed Web of Science ®Google Scholar
• Foody I, Farrell MH, Krumholz HM. β-blocker therapy in heart failure: scientific review. J Am Med Assoc. 2002;287:883–889.
   PubMed Web of Science ®Google Scholar